1. 224OPatient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). (24th November 2019) Authors: Friedlander, M L; Moore, K N; Colombo, N; Scambia, G; Kim, B-G; Oaknin, A; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, G S; Gourley, C; Banerjee, S; Oza, A; González-Martín, A; Aghajanian, C; Bradley, W; Lowe, E; Hettle, R; Flood, E; Disilvestro, P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 76 Patients (PTS) with recurrent gynecologic cancer whose tumors have activating wnt pathway mutations respond better to DKN-01, a DICKKOPF-1 (DKK1) inhibitor. (18th September 2019) Authors: Arend, R; Castro, C; Matulonis, U; Hamilton, E; Gunderson, C; LyBarger, K; Goodman, H; Duska, L; Mahdi, H; ElNaggar, A; Kagey, M; Barroilhet, L; Bradley, W; Sachdev, J; O'Malley, D; Sirard, C; Birrer, M Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LBA3Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. (25th November 2018) Authors: Friedlander, M; Moore, K; Colombo, N; Scambia, G; Kim, B-G; Oaknin, A; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, G S; Gourley, C; Banerjee, S; Oza, A M; González-Martín, A; Aghajanian, C; Bradley, W; Lowe, E S; Bloomfield, R; Disilvestro, P Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial. (1st November 2019) Authors: Moore, K; Colombo, N; Scambia, G; Kim, B-G; Oaknin, A; Friedlander, M; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, GS; Gourley, C; Banerjee, S; Oza, A; González-Martín, A; Aghajanian, C; Bradley, W; Mathews, C; Liu, J; Lowe, ES; Bloomfield, R Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗